Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
IGXT's Cash to Debt is ranked higher than
97% of the 1443 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. IGXT: No Debt )
IGXT' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: No Debt

Equity to Asset 0.73
IGXT's Equity to Asset is ranked higher than
77% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. IGXT: 0.73 )
IGXT' s 10-Year Equity to Asset Range
Min: -0.16   Max: 0.85
Current: 0.73

-0.16
0.85
Interest Coverage No Debt
IGXT's Interest Coverage is ranked higher than
75% of the 654 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IGXT: No Debt )
IGXT' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 10.74
M-Score: -0.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -107.29
IGXT's Operating margin (%) is ranked higher than
70% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -95.34 vs. IGXT: -107.29 )
IGXT' s 10-Year Operating margin (%) Range
Min: -855   Max: -87.43
Current: -107.29

-855
-87.43
Net-margin (%) -105.24
IGXT's Net-margin (%) is ranked higher than
70% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -77.05 vs. IGXT: -105.24 )
IGXT' s 10-Year Net-margin (%) Range
Min: -630   Max: -105.24
Current: -105.24

-630
-105.24
ROE (%) -34.27
IGXT's ROE (%) is ranked higher than
71% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. IGXT: -34.27 )
IGXT' s 10-Year ROE (%) Range
Min: -1461.46   Max: -36.45
Current: -34.27

-1461.46
-36.45
ROA (%) -28.40
IGXT's ROA (%) is ranked higher than
71% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. IGXT: -28.40 )
IGXT' s 10-Year ROA (%) Range
Min: -193.99   Max: -27.93
Current: -28.4

-193.99
-27.93
ROC (Joel Greenblatt) (%) -235.20
IGXT's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 1411 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. IGXT: -235.20 )
IGXT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -809.24   Max: -150.21
Current: -235.2

-809.24
-150.21
Revenue Growth (3Y)(%) 44.20
IGXT's Revenue Growth (3Y)(%) is ranked higher than
95% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. IGXT: 44.20 )
IGXT' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 44.2
Current: 44.2

0
44.2
EBITDA Growth (3Y)(%) -20.60
IGXT's EBITDA Growth (3Y)(%) is ranked higher than
64% of the 828 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. IGXT: -20.60 )
IGXT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 122.4
Current: -20.6

0
122.4
EPS Growth (3Y)(%) -20.60
IGXT's EPS Growth (3Y)(%) is ranked higher than
66% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. IGXT: -20.60 )
IGXT' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 141
Current: -20.6

0
141
» IGXT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with IGXT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 8.38
IGXT's Forward P/E is ranked higher than
99% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. IGXT: 8.38 )
N/A
P/B 9.70
IGXT's P/B is ranked higher than
53% of the 1612 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. IGXT: 9.70 )
IGXT' s 10-Year P/B Range
Min: 4.63   Max: 117
Current: 9.7

4.63
117
P/S 25.52
IGXT's P/S is ranked higher than
61% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 37.64 vs. IGXT: 25.52 )
IGXT' s 10-Year P/S Range
Min: 6.25   Max: 98.5
Current: 25.52

6.25
98.5
Current Ratio 3.07
IGXT's Current Ratio is ranked higher than
66% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.39 vs. IGXT: 3.07 )
IGXT' s 10-Year Current Ratio Range
Min: 1.07   Max: 6.45
Current: 3.07

1.07
6.45
Quick Ratio 3.07
IGXT's Quick Ratio is ranked higher than
67% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. IGXT: 3.07 )
IGXT' s 10-Year Quick Ratio Range
Min: 1.07   Max: 6.45
Current: 3.07

1.07
6.45
Days Sales Outstanding 143.45
IGXT's Days Sales Outstanding is ranked higher than
72% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. IGXT: 143.45 )
IGXT' s 10-Year Days Sales Outstanding Range
Min: 55.44   Max: 390.59
Current: 143.45

55.44
390.59

Valuation & Return

vs
industry
vs
history
Price/Net Cash 16.80
IGXT's Price/Net Cash is ranked higher than
75% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 107.00 vs. IGXT: 16.80 )
IGXT' s 10-Year Price/Net Cash Range
Min: 9.42   Max: 31
Current: 16.8

9.42
31
Price/Net Current Asset Value 13.40
IGXT's Price/Net Current Asset Value is ranked higher than
77% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. IGXT: 13.40 )
IGXT' s 10-Year Price/Net Current Asset Value Range
Min: 8.07   Max: 21.67
Current: 13.4

8.07
21.67
Price/Tangible Book 9.60
IGXT's Price/Tangible Book is ranked higher than
68% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 10.50 vs. IGXT: 9.60 )
IGXT' s 10-Year Price/Tangible Book Range
Min: 4   Max: 95
Current: 9.6

4
95
Price/Median PS Value 1.50
IGXT's Price/Median PS Value is ranked higher than
80% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. IGXT: 1.50 )
IGXT' s 10-Year Price/Median PS Value Range
Min: 0.46   Max: 2.57
Current: 1.5

0.46
2.57
Earnings Yield (Greenblatt) -4.40
IGXT's Earnings Yield (Greenblatt) is ranked higher than
71% of the 1398 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. IGXT: -4.40 )
IGXT' s 10-Year Earnings Yield (Greenblatt) Range
Min: -6.1   Max: 0
Current: -4.4

-6.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:IGX.Canada,
IntelGenx Technologies Corp. is a drug delivery company, that develops novel oral immediate release and controlled-release products for the branded and generic pharmaceutical market.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK